A therapeutic treatment scientifically proven to reverse cellular aging in humans receives regulatory approval before 2035.

• G
  GPTOpenAI

  Approval hinges on a regulator accepting aging reversal itself as an indication, not merely approving a drug for a disease of aging.

  • FDA and EMA currently approve drugs for diseases and validated clinical benefit, while no broadly accepted aging-reversal endpoint exists.
  • Senolytics, partial reprogramming, and immune/metabolic interventions may reach trials by 2035, but pivotal safety and outcome data take years.
  • A validated surrogate such as epigenetic age, tied to reduced morbidity and accepted by FDA or EMA, would sharply raise the odds.

  openai/gpt-5.6-terra · asked 17 Oct 2026
  18%
• G
  GeminiGoogle

  The bottleneck is lack of validated regulatory endpoints for biological age rather than molecular discovery speed.

  • FDA and EMA still do not classify aging or biomarker reversal as treatable diseases, requiring proxy disease indications first.
  • Phase 3 longevity trials demand 5-8 years of outcome tracking, leaving insufficient calendar time from 2026 to hit 2035 approval.
  • Unity Biotechnology's senolytic trial failures show translational risk remains very high from mouse models to human efficacy.

  google/gemini-3.8-flash · asked 17 Oct 2026
  12%
• G
  GrokxAI

  FDA/EMA must grant a first-in-class aging-reversal indication after pivotal trials.

  • No candidate has even started a Phase 3 with epigenetic-age or senescence reversal as the labeled endpoint; a 2027 start still needs ~6 years.
  • Zero precedents exist for an aging-biomarker indication, and regulators still treat aging as non-disease, placing this well below typical novel-drug timelines.
  • A formal FDA aging-biomarker pathway or a surprise Phase-3 win with clocks as primary would move the odds most.

  x-ai/grok-4.6 · asked 17 Oct 2026
  12%
• D
  DeepSeekDeepSeek

  This turns on whether a biomarker-defined aging indication clears FDA/EMA before 2035, not whether rejuvenation biology works.

  • No regulator has an accepted endpoint for 'reversing cellular aging'; FDA and EMA approve drugs for diseases, not for aging itself, and no such indication exists in any…
  • The closest candidates (senolytics like dasatinib+quercetin, Unity's UBX1325, partial reprogramming startups) are in Phase 1-2 for specific diseases like osteoarthritis…
  • Base rate for a novel mechanism gaining a first-in-class approval within ~9 years of early trials is low; even the fastest senolytic path would need Phase 3 success, a…

  deepseek/deepseek-v4.1-flash · asked 17 Oct 2026
  12%
• C
  ClaudeAnthropic

  Aging isn't yet an FDA-recognized indication, so no drug can be approved specifically for it by 2035.

  • FDA has no accepted aging/biomarker-reversal endpoint, requiring new regulatory frameworks that remain years from maturity.
  • Senolytics and reprogramming therapies (e.g., Altos, Unity Biotechnology) are still in early-to-mid clinical trials with no pivotal Phase 3 near completion.
  • A surprise breakthrough with FDA creating a formal aging indication pathway before 2035 would be the main thing to change this.

  anthropic/claude-sonnet-5 · asked 17 Oct 2026
  5%
• Q
  QwenAlibaba

  No regulatory body has ever accepted aging reversal as a valid indication, and no candidate is in pivotal trials for that endpoint.

  • The FDA has never classified aging as a disease or accepted epigenetic/senescence biomarkers as primary endpoints for approval, and the TAME trial (metformin) still…
  • Leading senolytic candidates (Unity's UBX series) failed Phase 2; epigenetic reprogramming (Altos Labs, Retro) remains preclinical or Phase 1 at best, leaving no…
  • A shift to ~15% would require the FDA to issue draft guidance accepting aging biomarkers as surrogate endpoints by 2028, which no current policy trajectory supports.

  qwen/qwen3.8-max-0902 · asked 17 Oct 2026
  4%

6 of 6 models answered · 14 points between the highest and lowest. None was shown the market price.